Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply
N Engl J Med
.
2019 Nov 21;381(21):2076-2077.
doi: 10.1056/NEJMc1913157.
Authors
Mansoor Husain
1
,
Morten Donsmark
2
,
Stephen C Bain
3
Affiliations
1
Ted Rogers Centre for Heart Research, Toronto, ON, Canada.
2
Novo Nordisk, Søborg, Denmark.
3
Swansea University Medical School, Swansea, United Kingdom.
PMID:
31747740
DOI:
10.1056/NEJMc1913157
No abstract available
Publication types
Letter
Comment
MeSH terms
Diabetes Mellitus, Type 2*
Glucagon-Like Peptides
Humans
Hypoglycemic Agents
Substances
Hypoglycemic Agents
semaglutide
Glucagon-Like Peptides